

SANS Risk Directed Acyclic Graph – DAG Narrative

- ❖ **Altered Gravity** removes (0 g) or reduces (partial g) the hydrostatic pressure gradient, causing a cephalad Fluid Shifts within the arterial and venous systems and within the cerebrospinal fluid column. **Individual Factors** such as age, sex, genetic predispositions, pre-existing medical conditions and more influence variability in biologic response to the spaceflight environment. This can affect multiple nodes discussed below.
- ❖ These cause physiologic changes including **Venous Congestion** and possibly **Intracranial Pressure Changes** in the brain. **CO₂ (Risk)** and **Sleep (Risk)** may have a causal connection to **Intracranial Pressure Changes** as CO₂ is known to cause vasodilation of cerebral arterioles, and impaired sleep may reduce lymphatic/glymphatic clearance from the brain and eye. Invasive measures of **Intracranial Pressure Changes** have not been obtained in-flight.
- ❖ These physiologic changes are hypothesized to underlie the structural changes in the eye including **Optic Disc Edema, Globe Flattening, and Chorioretinal Folding**. Terrestrially, **Optic Disc Edema** can lead to **Retinal Nerve Fiber Layer Atrophy**, but this has not been observed in the astronaut population.
- ❖ In-mission, these structural changes lead to functional changes in the eye including **Refractive Error Shifts**, and reversible **Visual Field Defects** have been detected postflight. These in turn affect **Individual Readiness** for mission tasks that can progressively affect **Crew Capability** and **Task Performance** overall.
- ❖ **Cardiovascular (Risk)** may have a causal connection to the possibility of vascular disruption and leakage at the blood-retinal and/or blood-brain barrier resulting from radiation exposure beyond low earth orbit.
- ❖ **Brain Structural Changes** are hypothesized to result from the cephalad fluid shift, but potential acute performance effects and/or **Long-Term Health Outcomes** are unknown.
- ❖ To characterize the risk, **Surveillance** is required to **Detect Long Term Health Outcomes** that may present as cognitive or visual decrements post-flight or post-career.
- ❖ To assess and counteract the SANS issues in flight, the **Vehicle Design** must include a **Crew Health and Performance System** that provides mass and volume allocations for several countermeasure pathways. Inclusion of these are affected by the **EIHSO (Risk)**.
 - **Medical Prevention Capabilities** include:
 - **Astronaut Selection** affects and limits the **Individual Factors** present in the crewmembers. Those Individual Factors affect the degree of bio variability of multiple nodes including **Brain Structure Changes, Intracranial Pressure Changes, Vascular Congestion, Optic Disc Edema, Globe Flattening, Chorioretinal Folds, Retinal Nerve Fiber Layer Atrophy, Refractive Error Shift and Visual Field Defects**. This does not imply that all outcomes that may be influenced by **Individual Factors** are assessed at **Astronaut Selection**.
 - **Lower Body Negative Pressure** is under consideration as a preventive countermeasure for many effects of **Fluid Shifts**.
 - **Veno-occlusive Thigh Cuffs** may reduce **Fluid Shifts** and may improve **Venous Congestion** and **Intracranial Pressure Changes**.

- **Supplements** such as B vitamins are hypothesized to affect homocysteine pathways and improve microvascular function and reduce edema. These are related to the **Food and Nutrition (Risk)**.
- **Medications** have been considered to prevent **Intracranial Pressure Changes** and these are affected by the **Pharm (Risk)**
- **Monitoring Capabilities** include:
 - Hardware currently in use on ISS requires real-time remote guidance support that will be impacted by communication delays with increased distance from Earth.
 - **Optical Coherence Tomography** is used pre-, post-, and in-flight to assess the retina, choroid, and optic nerve head.
 - In-flight **Fundoscopy** to assess gross structural changes in the optic nerve head and retina
 - Pre- and post-flight **MRI** to track structural changes in the eye and brain.
 - Pre-, post-, and in-flight Ultrasound to assess structural changes within and posterior to the eye
 - **Visual Acuity Tests** and **Visual Field Tests** assess the optical fidelity functional state of the eye. These allow us to **Detect Visual Changes** and guide **Medical Treatment Capability** in-mission.
 - In-Flight direct **Intracranial Pressure Monitoring** is of interest but has not been performed to date. It is speculated that this information could enable us to **Detect Intracranial Pressure Changes** and that information could be used to guide **Medical Treatment Capabilities** in the future.
- **Medical Treatment Capabilities**
 - **Corrective Lenses** are the current treatment modality in-mission for visual changes that may affect **Individual Readiness**.
This requires the ability to provide corrective lenses with the appropriate corrective power.
 - There is currently no proven inflight pharmaceutical treatment available for SANS.
- ❖ **Flight Recertification** has been affected when ocular structure changes (e.g., severe **SANS findings**) and **Intracranial Pressure Changes** have been **detected** post flight.

